SCHEMBL30889

SCHEMBL30889

CC(C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MME P08473 11/20 0.68
ACE P12821 3/20 0.68
MMEL1 Q495T6 8/20 0.67
CTSS P25774 1/20 0.57
CTSK P43235 1/20 0.57
ATM Q13315 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21572793 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL3877643 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL1908539 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL597902 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL29046 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL29983 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL3867666 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL13566634 1.00 MME (0.68) MMEACEMMEL1CTSSCTSK
SCHEMBL1232351 0.99 MME (0.67) MMEACEMMEL1CTSSCTSK
SCHEMBL1231233 0.99 MME (0.67) MMEACEMMEL1CTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946481-B2 Process for preparing biaryl substituted 4-amino butyric acid or derivatives thereof and their use in the production of NEP inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946481-B2 Process for preparing biaryl substituted 4-amino butyric acid or derivatives thereof and their use in the production of NEP inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20130066101-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS NOVARTIS AG (CH) 2013-03-14 US disclosed
US-20130066101-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS NOVARTIS AG (CH) 2013-03-14 US disclosed
US-20090326066-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS NOVARTIS AG (CH) 2009-12-31 US disclosed
US-20090326066-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS NOVARTIS AG (CH) 2009-12-31 US disclosed
EP-1903027-A1 Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors Novartis AG (CH) 2008-03-26 EP disclosed
WO-2008031567-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS NOVARTIS AG (CH) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130066101-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS MME, REN, BCAT2 MME 1/4885ACE 5/4885MMEL1 776/4885
US-20090326066-A1 PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS MME, REN, BCAT2 MME 1/4885ACE 5/4885MMEL1 697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.